logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
22/05/2026
The trading volume of the Shanghai and Shenzhen stock markets exceeded 2 trillion yuan, down 301.3 billion yuan from the previous day at this time.
Latest
2 m ago
Daiwa: Xiaomi Group -W (01810) introduces YU7 GT to help achieve electric vehicle delivery targets.
5 m ago
Daiwa Securities analysts stated in a report that with a diversified product line, Nio is preparing to enter a new vehicle cycle. Nio will launch the ES9 on May 27 and introduce a new five-seat version of the ES8 in the second half of the year. They mentioned that the company plans to launch three to five new models in the coming years while also planning to build 1000 battery swapping stations this year. After Nio announced strong first quarter results, Daiwa raised its profit forecast for 2026 and 2027. The institution maintains a buy rating on Nio.
6 m ago
Haitong International: Initiates Maikel Intelligent Chip (09903.HK) with "Outperform" rating and a target price of 596.7 Hong Kong dollars.
6 m ago
Glass substrate concept rises again BOE Technology Group A shares rise for the second consecutive day
7 m ago
Sinopharm: the Envida NSCLC phase III clinical trial for adjuvant/neoadjuvant therapy has completed the enrollment of all subjects.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.